Skip to main content
Research Podcast Cover
Research News

Episode 6: Impacts and Goals of the Global Parkinson's Genetics Program with Dr. Christine Klein

A substantial portion of people with Parkinson's disease (PD) have a family history of the disease, and new findings continue to improve our understanding of relevant genetic variants. These discoveries are key for clarifying the mechanisms that lead to Parkinson's disease as well as the development of new therapies. The Global Parkinson's Genetics Program (GP2) was established to gather and integrate genetic and clinical data from diverse participants around the world to expand our knowledge of the genetic architecture of PD. In this episode, Dr. Christine Klein discusses her experiences as Co-Leader of the Monogenetic Network of GP2, including the early days of setting up this large-scale collaboration, important achievements to date, and priorities and considerations going forward. She also shares recent findings from her own research on genetic variants related to Parkinson's disease. Christine is Director of the Institute of Neurogenetics and of the Section of Clinical and Molecular Neurogenetics at the Department of Neurology, as well as the Schilling Professor of Neurology at the University of Lübeck in Germany. She is also Co-Director of the Monogenetic Network of GP2. 

This podcast is geared toward researchers and clinicians. If you live with Parkinson’s or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson’s Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

Rather listen on-the-go?  Subscribe to The Parkinson’s Research Podcast: New Discoveries in Neuroscience on iTunes or through any podcast app on your smartphone or tablet. 

View the transcript of this podcast. 

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.